Duchenne muscular dystrophy (DMD) is an X-linked muscle disorder characterized by progressive, irreversible loss of cardiac and skeletal muscular function.
| INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked muscle disorder characterized by progressive, irreversible loss of muscular function, [1] [2] [3] due to the lack of dystrophin, a large membrane-associated protein, expressed in striated muscles/heart and localized to the sarcolemma. 4, 5 The incidence of DMD is one in 3500 male newborns with a prevalence of six in 100 000 males. 6 Dystrophin is a component of the dystrophin-glycoprotein complex that serves as a connection between the large complex of glycoproteins in the muscle cell membrane and intracellular actin filaments; it is in charge of transmitting forces generated by sarcomere contraction to the extracellular matrix.
The most pathognomonic sign of DMD is the disproportion between size and strength of the skeletal muscles; this sign is most prominent in the enlarged calves. In 1860, Duchenne described this sign and named the disease as "paralysie musculaire pseudo-hypertrophique". 10 A muscular oedema that could contribute to calves' enlargement had been already identified and was attributed to an interstitial inflammation. 11 However, the oedema is mainly due to the increased cytoplasmic concentration of Na+ and is osmotic rather than interstitial inflammatory, as initially assumed. 12 As DMD is characterized by a gonosomal transmission, female patients with DMD have rarely been described. 13 Although most heterozygous female carriers of DMD mutations are asymptomatic, some of them may present with mild thigh weakness, oedema, myalgia or muscle cramps; later onset of symptoms suggests less severe disease. 13 The recent use of eplerenone in carriers resulted in reduced circumferences of thighs, as a result of oedema reduction, granted that muscular strength was not improved. 14 An increased sodium conductance is the cause of membrane depolarization in DMD muscle; 12 as a consequence, cytoplasmic sodium overload takes place, which may be strong enough osmotically to cause oedema. Subsequent membrane repolarization may restitute ion and water homoeostasis and membrane excitability. A possible endogenous mechanism able to reduce sodium overload in muscle may be the sodium-proton exchanger (NHE). In the heart muscle, NHE was identified as a mineralocorticoidregulated inducer of inflammation and fibrosis. 15 This regulation contributes to the beneficial effects of the mineralocorticoid receptor blocker spironolactone in preserving cardiac and skeletal muscle function in mdx mice. 16 The aim of this review was to present the existing experience in the field and emphasize the role of cardiovascular magnetic resonance (CMR) in the evaluation of these patients both diagnostically and to monitor their disease activity.
| CARDIAC DISEASE IN DUCHENNE MUSCULAR DYSTROPHY
Duchenne muscular dystrophy patients' prognosis depends mainly on ventilatory assistance, as respiratory muscle dysfunction was the most common cause of their death. However, after the third decade of life, most of the patients with DMD develop cardiomyopathy/heart failure that is not clinically overt, due to their relative physical inactivity. 17 Cardiomyopathy is currently the main cause of death in DMD, and myocardial tissue lesions usually precede the reduction in left ventricular (LV) systolic function. Interestingly, the severity and the evolution of cardiomyopathy do not correlate with the type of dystrophin mutation. 18 In DMD with preserved LV ejection fraction, the addition of eplerenone, another mineralocorticoid receptor antagonist, to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), attenuates the progressive decline in LV systolic function. 19 Angiotensin-converting enzyme inhibitors have been proven effective in the prevention of LV remodelling in ischaemic cardiomyopathy by reducing LV hypertrophy and fibrosis, which may lead to ventricular arrhythmias and sudden cardiac death (SCD). 20 ACE inhibitors have been also studied in DMD. Early initiation of treatment with perindopril was associated with lower mortality in DMD with normal LV ejection fraction at study entry. 21, 22 Other studies documented that a beta-blocker (BB), in addition to an ACE inhibitor, improves LV systolic function in DMD. These encouraging results suggest initiation of ACE inhibitors and/or BB soon after diagnosis of the muscular dystrophy, especially DMD. 23, 24 Screening and therapy of arrhythmias is an underevaluated area in DMD. There is an increase in sudden cardiac death in DMD, and in advanced cases, cardiomyopathy and cardiac arrhythmias are similar to those seen in other cardiomyopathies, including atrial fibrillation/flutter, ventricular tachycardia and fibrillation. The presence of late gadolinium enhancement (LGE) on CMR was associated with increased arrhythmia risk in DMD. 23, 24 These patients may benefit from following the heart failure guidelines for primary arrhythmia prevention and the risk/benefit ratio for implanted cardiac defibrillators (ICDs) in those with an LV ejection fraction <35% should be considered. It should be noted that the risk of intervention may be greater in the DMD population, because the severe kyphoscoliosis and respiratory muscle weakness commonly found in patients with advanced DMD may increase the risks associated with ICD implantation. The use of biventricular pacing in DMD has not been assessed yet. However, the pattern of inferolateral fibrosis, assessed by CMR in DMD cardiomyopathy, is similar to the pattern associated with a lack of response to resynchronization therapy in the general heart failure population. 25 Furthermore, mechanical dyssynchrony is frequent in end-stage DMDs with cardiac dysfunction and is associated with normal QRS and extensive lateral fibrosis. Therefore, it is unlikely that this patient population will benefit from CRT. 26 Cardiac disease in female carriers of dystrophinopathies may present with hypertrophy, arrhythmias or dilated cardiomyopathy. 27 Clinically overt cardiac disease increases with age in carriers, from 15% in fewer than 16 years to 45% in longer than 16 years. However, the significant cardiac disease is rather unusual in female carriers at an age younger than 16 years. 19 In a study of 85 DMD and 44 Becker muscular dystrophy (BMD) carriers, aged 18-58 years, dilated cardiomyopathy was found in 18% and 8%, respectively. | ECG changes were documented only in 47% of this population. 29 In another series of 56 adult female carriers, no ECG changes were observed; however, ventricular dilatation or hypertrophy was documented in 14% and dilated cardiomyopathy in 7% of them. 30 Yet, severe heart failure may develop in some women necessitating heart transplantation to survive. 22, [25] [26] [27] 31, 32 Exercise and CMR may unmask LV systolic dysfunction in female carriers. 28, 33 CMR documented myocardial fibrosis in the majority of DMD and BMD mother-carriers, although the clinical presentation and the usual noninvasive assessment were normal or mildly impaired. 34 These findings support a detailed cardiac evaluation after the teenage years in all female carriers to start cardiac medication as early as possible. 35 Although the cardiac medication cannot halt the progression of cardiac involvement, every morphologic or functional cardiac abrormality detected by any technique should be treated according to ESC and ACC/AHA/HFSA heart failure guidelines. 36 
| ROLE OF CMR IN THE EVALUATION OF MYOCARDIAL DISEASE IN DMD
Echocardiography represents the cornerstone technique in cardiology. However, it is the operator and acoustic window depending and cannot perform tissue characterization for subclinical disease detection. 37 Specifically, in DMD, the comparison of CMR vs echocardiography documented that three-quarter of echocardiography studies had suboptimal windows and 26% of measurements significantly overor underestimated the left ventricular function compared to CMR. 38, 39 According to our opinion, although echocardiography remains a first line, cost-effective, widely available technique, CMR is absolutely necessary for subclinical disease detection, risk stratification and treatment assessment. Cardiovascular magnetic resonance using cine sequences measures ventricular volumes and ejection fraction without using a contrast agent and provides three-dimensional images of the heart, also feasible with 3D echocardiography. Of note, CMR volumes and ejection fraction are more accurate and reproducible than those provided by other techniques, although a good correlation between CMR and these techniques has been reported. 40 Cardiovascular magnetic resonance is the most reliable imaging technique to detect and quantify fibrotic tissue (viability study). This tissue retains the paramagnetic contrast agent gadolinium and, therefore, appears bright. 41 The preferred time for fibrosis imaging is 15-20 minutes after the contrast agent injection, when the differences between fibrotic tissue, normal myocardium and blood are at the maximum. This method is known as late gadoliniumenhanced CMR (LGE) and is the gold standard for the in vivo assessment of myocardial fibrotic tissue, granted that CMR can detect fibrosis in as little as 1 cm 3 of tissue, significantly less than other in vivo techniques, while it has an excellent correlation with histology. 41 Many studies have proved the presence of myocardial fibrosis in both DMD and carriers, emphasizing its role as an early strong diagnostic index of cardiac disease and as a reliable indication for an early start of cardiovascular treatment 42 ( Figure 1 ).
LGE always represents replacement fibrosis and not fatty infiltration, as it has been already documented by relevant pathology studies. 43 Fibrosis is seriously involved in the pathophysiology of cardiac involvement of DMD, presenting both a replacement and a diffuse pattern, as it was documented by various published studies. 37, 42, 44 A recent CMR assessment of patients with nonischaemic cardiomyopathy documented that LGE was a powerful and independent predictor of malignant arrhythmia prognosis. 45 
| CMR INDICES FOR DMD EVALUATION
According to previously discussed pathophysiologic mechanisms, myocardial oedema seems to play an important role in the development of cardiac lesions in DMD. CMR is the only noninvasive technique that can reliably identify the presence of myocardial oedema. To achieve this target, T2w-STIR, T2 mapping and Native T1 mapping should be used.
| T2-weighted imaging
T2-weighted short-tau inversion recovery (STIR T2W) imaging (Figure 2 ) is the most commonly used approach to detect myocardial oedema, because it suppresses the signal from moving blood/fat and enhances sensitivity to myocardial tissue fluid, characteristic of the oedematous myocardium. Myocardial oedema is the first reaction of heart against any damage and represents acute lesion irrespective of aetiology. In ischaemic heart disease is the technique of choice to discriminate acute from chronic lesions. In acute myocarditis, T2w hyperintensity may be either focal, as in 30% of patients, or diffuse as in the remaining 70%, and may be the only marker of the disease. Tissue oedema may also be observed in other conditions, such as primary cardiomyopathies (CMP), storage diseases, pulmonary hypertension, cardiac transplant rejection 46 and asymptomatic, treatment na€ ıve patients with autoimmune rheumatic diseases. 47 These findings emphasize the role of oedema as an early marker of pathophysiologic phenomena occurring in various myocardial diseases. However, STIR T2W sequences have suffered from several problems including a) signal intensity variability caused by phased array coils, b) high signal from slowmoving intraventricular blood that can mimic elevated T2 in the subendocardial myocardium, c) motion artifacts and d) the subjective nature of T2W image interpretation. In contrast to STIR T2W images, T2 mapping did not show any signal variation and was insensitive to cardiac motion. Therefore, the use of quantitative T2 mapping offers a clinically applicable solution of the problems associated with STIR T2W imaging and offers better accuracy in the detection of cardiac oedema. 48 The T2 values derived from the T2 mapping of human myocardium were 52.18 AE 3.4 ms (range: 48.96 ms-55.67 ms), with variability between subjects unrelated to heart rate. Unfortunately, the combination of T2W-STIR and T2 mapping cannot differentiate the intracellular from extracellular oedema. However, the T2 mapping is currently considered as the best approach to detect and quantify myocardial oedema. 49 
| T1 mapping
T1 mapping is currently a clinically feasible technique providing pixel-wise quantification of the cardiac structure's T1 values. The strength of this method is based on its high reproducibility and immediate clinical applicability, even without the use of contrast agent (native or pre-contrast T1). The two most important determinants of native T1 augmentation are 1 oedema related to tissue water increase (recent infarction or inflammation) and 2 interstitial space increase related to fibrosis (infarction scar, cardiomyopathy) or amyloidosis ( Figure 3 ). Conversely, lipid (Anderson-Fabry) or iron overload diseases are responsible for the T1 reduction. Although replacement fibrosis can be well depicted by late gadolinium enhancement (LGE), the T1 mapping is the only index that can discriminate diffuse myocardial alterations, not accessible by noninvasive means. 50 Furthermore, quantitative imaging of extracellular volume fraction (ECV) can characterize myocardial infarction, atypical diffuse fibrosis and subtle myocardial abnormalities not apparent on LGE images. 51 There are only few publications on the role of oedema imaging in DMD. According to a recent study, native T1 values are increased in DMD and this finding may serve as an early marker of diffuse fibrosis. 52 However, in another study, the majority of DMD subjects had normal or decreased T2. 53 Yet another study using quantitative maps of T1 and T2 relaxation times and muscle fat fraction
showing diffuse oedema in a DMD patient. T2 signal intensity of heart/T2 signal intensity of skeletal muscle = 3 (normal < 2)
F I G U R E 3 T1 mapping in a DMD patient showing increased T1 = 1120 msec measurements of the upper arm skeletal muscles and heart in ambulatory boys with DMD and age-matched healthy volunteers, the cardiac-optimized sequences detected fatty infiltration and oedema in the upper arm skeletal muscles but not the myocardium in these DMDs with normal ejection fraction. 54 Finally, the evaluation of extracellular cardiac volume (ECV) in patients with DMD is a useful tool to assess the total extent of myocardial fibrosis, as well as to depict subtle, diffuse fibrosis in areas of normal-appearing myocardium on LGE images. Thus, myocardial ECV is a potential additional quantitative tool for accurate detection of cardiac involvement and risk stratification in patients with DMD. 52 Abnormalities of T2 relaxation time in the myocardium and sternocleidomastoid muscles (SCM) of DMD patients without cardiorespiratory symptoms, indicating altered tissue composition, have been already described 55 ; in these patients, the use of deflazacort offered a better preservation of the T2 relaxation time of myocardium and sternocleidomastoid muscles and better LV systolic function. 56 However, these studies were performed using old technology and lower magnetic field than the 1.5 T systems that are currently used. Performing the same evaluation using 1.5 T and new T2w imaging, we identified an increase in myocardial T2 values in a significant percentage of our patients with DMD indicative of oedema (unpublished data). Furthermore, patients with DMD may be more prone to myocarditis than control subjects, because the abnormal dystrophin behaves as a vehicle for different viruses. 57, 58 However, during the early stages, it may remain undetected by echocardiography, which is unable to perform tissue abnormalities, occurring without associated changes in LVEF; furthermore, the diagnosis of myocarditis can be missed, because an increase in cardiac troponin was detected in only 20% of cases. [54] [55] [56] 59 Cardiovascular magnetic resonance diagnoses myocarditis using three types of images according to Lake Louise criteria 60 : T2-weighted (T2-W), early T1-weighted (EGE) images taken 1 minute after injection of the contrast agent (EGE) and delayed enhanced images (LGE). A combined CMR approach, using T2-W, EGE and LGE, has a sensitivity of 76%, a specificity of 95.5% and a diagnostic accuracy of 85% for the detection of myocarditis. Myocarditis, missed by other noninvasive techniques, has been already described in DMD using CMR, which may have serious implications in the patients' treatment, risk stratification and prognosis. 58 Recently, the clinical utility of T2 and T1 mapping has been evaluated in myocarditis. However, the results are still conflicting. A study comparing the classic Lake Louise criteria with T2 and T1 mapping proved that ECV and native (noncontrast) T1 mapping perform at least equally well in comparison with established Lake Louise criteria. 61 In a study by Radunski et al., it was proved that native (noncontrast) T1 and ECV mapping reveal hidden a myocardial injury in the normal-appearing myocardium of patients with myocarditis, and therefore, the amount of myocardial injury in myocarditis was underestimated by conventional LGE imaging. 62 Furthermore, Esposito et al. supported that CMR sensitivity varies in acute myocarditis, reflecting its clinical polymorphism and the intrinsic drawbacks of Lake Louise criteria. For this reason, semiquantitative approaches such as EGE or T2 ratio have limited accuracy in diffuse forms. of myocarditis. The authors hypothesized that a revised protocol including T2-STIR, T1 mapping and LGE could potentially improve sensitivity. 63 According to our opinion, this seems the most realistic approach at the moment.
| CONCLUSIONS
The assessment of cardiac oedema and subepicardial fibrosis in the inferolateral wall of the left cardiac ventricle represent the cornerstones of the pathophysiologic process occurring in DMD and are the most important early findings in patients with preserved ventricular function. CMR, using both the classic and the new indices for oedemafibrosis evaluation, represents the best technique to early detect subclinical cardiac lesions and risk stratify patients with DMD.
